Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Postpartum Sexual Function in Pregnant Women With COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04389489
Recruitment Status : Recruiting
First Posted : May 15, 2020
Last Update Posted : September 2, 2020
Sponsor:
Information provided by (Responsible Party):
Merve Aldikactioglu Talmac, MD, Kanuni Sultan Suleyman Training and Research Hospital

Brief Summary:
The aim of this study is to identify women with postpartum sexual dysfunction and dyspareunia risk in the early period and to use the treatment and care services they need effectively. Our secondary aim is to reveal the difference in sexual life in the postpartum period between healthy pregnant women and pregnant women diagnosed with COVID-19.

Condition or disease
COVID-19 Dyspareunia Postpartum Period

Layout table for study information
Study Type : Observational
Estimated Enrollment : 140 participants
Observational Model: Ecologic or Community
Time Perspective: Prospective
Official Title: Evaluation of Pregnant Women Diagnosed With COVID-19 Using Carol Postpartum Sexual Function and Dyspareunia Scale
Actual Study Start Date : May 14, 2020
Estimated Primary Completion Date : September 25, 2020
Estimated Study Completion Date : September 30, 2020

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale [ Time Frame: 3 months ]
    In the study planned to be carried out, it is aimed to identify women at risk of postpartum sexual dysfunction and dyspareunia early and benefit from the treatment and care services they need effectively.


Secondary Outcome Measures :
  1. Evaluation of pregnant women diagnosed with COVID-19 using Carol Postpartum Sexual Function and Dyspareunia Scale [ Time Frame: 3 Months ]
    To reveal the difference in sexual life in postpartum period between healthy pregnant women and pregnant women diagnosed with COVID-19.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
In the reproductive age between 18-45 years old, two groups of 70 people will be selected, consisting of puerperant diagnosed with COVID-19 and healthy puerperant. Patients who have cesarean or vaginal delivery at the end of the study group, who do not have sexual intercourse dysfunction for another reason (such as Stage 3-4 perineal injury, vaginismus) will be selected.
Criteria

Inclusion Criteria:

  • Pregnant Patient with COVID-19

Exclusion Criteria:

  • Those with known sexual dysfunction disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04389489


Contacts
Layout table for location contacts
Contact: Merve Aldikactioglu Talmac, M.D. +905325602366 drmrve@hotmail.com

Locations
Layout table for location information
Turkey
Kanuni Sultan Suleyman Training and Research Hospital Recruiting
Istanbul, Halkali, Turkey, 34307
Contact: Merve Aldikactioglu Talmac, M.D.    +905325602366    drmrve@hotmail.com   
Sponsors and Collaborators
Kanuni Sultan Suleyman Training and Research Hospital
Publications:
Layout table for additonal information
Responsible Party: Merve Aldikactioglu Talmac, MD, Specialist of Obstetrics and Gynecology, Kanuni Sultan Suleyman Training and Research Hospital
ClinicalTrials.gov Identifier: NCT04389489    
Other Study ID Numbers: MTalmacCarol
First Posted: May 15, 2020    Key Record Dates
Last Update Posted: September 2, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Merve Aldikactioglu Talmac, MD, Kanuni Sultan Suleyman Training and Research Hospital:
Postpartum Period
Dyspareunia
COVID-19
Additional relevant MeSH terms:
Layout table for MeSH terms
Dyspareunia
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Mental Disorders